Articles - Results from #40

mCRPC Treatment: The Right Treatment for the Right Patient at the Right Time

Published in Everyday Urology - Oncology Insights: Volume 1, Issue 4

Published Date: December 2016

Metastatic castration-resistant prostate cancer (mCRPC) presents with a wide spectrum of symptoms with varying effects on patient quality of life. It is estimated that more than 90% of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases that result in a significant increase in the risk of morbidity.1

First of its Kind: A Core Curriculum for Urologic Nursing

Published in Everyday Urology - Oncology Insights: Volume 1, Issue 4

Published Date: December 2016

The Core Curriculum is a first-of-its-kind textbook that can be used by nurses to study for specialty certification as a urology registered nurse, and is a source of material to support urology nursing instruction in academic programs. It has applicability to nurses in acute care, long term care, home care and rehab settings as all encounter patients with urologic problems.

Bladder Cancer BioMarkers: Optimal Utilization for Diagnosis and Recurrence

Published in Everyday Urology - Oncology Insights: Volume 1, Issue 3

Published Date: September 2016

Voided urine cytology has been the gold standard for detecting bladder cancer since 1945. Its specificity nears 90%, meaning that a positive result is highly reliable. But cytology is unreliable for detection of low grade tumors such that only about 20% to 30% of low grade bladder tumors are identified using cytology.

Emerging Therapies for BCG-Unresponsive Nonmuscle-Invasive Bladder Cancer

Published in Everyday Urology - Oncology Insights: Volume 1, Issue 3

Published Date: September 2016

About 70,000 new bladder cancer cases are diagnosed annually in the United States, and about 15,000 patients die as a result.[1) Approximately 60% to 70% of cases are non-muscle invasive bladder cancer (NMBIC). Because the incidence of NMIBC substantially exceeds its mortality rate, the best indicator of its impact is its prevalence of about 700,000 cases nationwide.

Systemic Immunotherapy Bladder Cancer.. Get Ready!

Published in Everyday Urology - Oncology Insights: Volume 1, Issue 3

Published Date: September 2016

Daniel George, MD, is Professor of Medicine and Surgery and Director of Genitourinary Oncology at the Duke Cancer Institute. In the following article, he provides his perspective on new developments in the use of systemic immunotherapy.

Axumin™ [Fluciclovine F18]: An Accurate Imaging Approach for Patients with Biochemically Recurrent Prostate Cancer

Published in Everyday Urology - Oncology Insights: Volume 1, Issue 2

Published Date: June 2016

Prostate cancer [PCa] affects 1 man in 7 in the United States, making this the most commonly diagnosed non-cutaneous cancer in males. Although an ever-increasing number of treatment options exist, an estimated 26,100 men will still die of the disease in the US in 2016, generally after primary local and systemic treatments for prostate cancer have failed.

The Story of the COU-AA-302 Clinical Trial: Highlights From the Journey - Full-Text Article

Published in Everyday Urology - Oncology Insights: Volume 1, Issue 2

Published Date: June 2016

Charles J Ryan, MD, is a leader in medical oncology and was the primary investigator for the COU-AA-302 clinical trial, which led to FDA approval of abiraterone acetate plus prednisone as the first oral therapy for treatment in chemotherapy-naïve metastatic castration-resistant prostate cancer. Dr. Ryan is Professor of Clinical Medicine and Urology and Thomas Perkins Distinguished Professor in Cancer Research, and Program Leader, Genitourinary Medical Oncology at the University of California-San Francisco Helen Diller Family Comprehensive Cancer Center in San Francisco, CA. In the following article, he reflects on the highlights of the COU-AA-302 journey, including the pioneering results and methodology of the study, as well as the voice of the study results including the secondary endpoints on patient outcomes such as pain, time to opiate use, and functional status.

Bone Metastases and Mortality in Prostate Cancer, Can We Be Doing More? - Full-Text Article

Published in Everyday Urology - Oncology Insights: Volume1, Issue 2

Published Date: June 2016

Prostate cancer is the most common malignancy among US men, with an estimated annual incidence of 180,890, accounting for one in five new cancer cases in men.¹ The second-most common cause of cancer death in US men, prostate cancer is expected to claim the lives of 26,120 men in this country in 2016.¹

The Changing Role of the Radiologist/Nuclear Medicine Physician in the Management of Advanced Prostate Cancer Patients - EVERYDAY UROLOGY- Full text article

Published in Everyday Urology - Oncology Insights: Volume 1, Issue 1

Published Date: March, 2016

The several new therapies recently approved for the treatment of metastatic castrate resistant prostate cancer patients have altered the roles of various healthcare providers practicing in this space. For example, urologists have become more actively involved in the management of castrate resistant prostate cancer patients. With regards to imaging, the advances in therapy have created an urgent need to develop better technologies to detect and monitor metastatic disease. Radiology and nuclear medicine practices are also changing as we expand beyond diagnostic imaging to include more longitudinal therapeutic care to our patients through the administration of radium 223 to our castrate resistant patients with symptomatic bone metastases.

Considerations in the use of Androgen Deprivation Therapy for the Treatment of Men with Advanced Prostate Cancer - EVERYDAY UROLOGY- Full text article

Published in Everyday Urology - Oncology Insights: Volume 1, Issue 1

Published Date: March, 2016

It was October 20, 2010, when the U.S. Food and Drug Administration asked manufacturers to add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer. The warnings alert patients and their health care professionals to the potential risk of heart disease and diabetes in men treated with these medications.

Embarrassment of Riches: Therapies that Improve Overall Survival in mCRPC

Published in Everyday Urology - Oncology Insights: Volume 1, Issue 1

Published Date: March, 2016

Before 2004, there was an unmet need for survival prolonging therapies in men with castration-resistant prostate cancer (CRPC). Palliative therapeutic options were the standard of care. As a result, there was a pervasive nihilism regarding the therapeutic management of men with advanced prostate cancer, especially after they ceased responding to androgen suppressive therapy.

Page 3 of 3

Login